Showing 20 of 37 recruiting trials for “aggressive-primary-cutaneous-t-cell-lymphoma”
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
👨⚕️ Christopher Jensen, MD MSCR, UNC Lineberger Comprehensive Cancer Center📍 1 site📅 Started Jun 2025View details ↗
CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
👨⚕️ Tengyu Wang, Ph.D, Beijing GoBroad Hospital, Beijing, Beijing 102200📍 3 sites📅 Started Jun 2025View details ↗
RecruitingNCT07132567 ↗
Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA
RecruitingNCT06588868 ↗
Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma
👨⚕️ Pietro Quaglino, MD, SC Dermatologia U - A.O.U. Città della Salute e della Scienza di Torino📍 18 sites📅 Started Feb 2025View details ↗
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RecruitingNCT07003100 ↗
A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab
RecruitingNCT06436677 ↗
A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
RecruitingNCT06207812 ↗
Long-term Outcomes Associated With Juvenile-onset Mycosis Fungoides and Lymphomatoid Papulosis
RecruitingNCT06382844 ↗
Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL
👨⚕️ Julia M Almeida Parra, Prof., Instituto de Investigación Biomédica de Salamanca📍 1 site📅 Started Jan 2024View details ↗
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
👨⚕️ Ryan Wilcox, University of Michigan Rogel Cancer Center📍 1 site📅 Started Dec 2023View details ↗
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
Page 1 of 2Next →
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →